Finoriq research workspace
Aptevo Therapeutics Inc. (APVO) SEC Filings & Filing Highlights
Aptevo Therapeutics Inc. develops its products using ADAPTIR and ADAPTIR-FLEX platforms to. Review APVO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
- Company
- Aptevo Therapeutics Inc. (APVO)
- Ticker
- APVO
- Market Cap
- $5.9M
- Latest Price
- $4.77
- Industry
- Biotech & Pharma
Aptevo Therapeutics Inc. (APVO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aptevo Therapeutics Inc. (APVO).
| Event | Form | Date |
|---|---|---|
| Aptevo Secures $1.5 Million Non-Dilutive Research Grant from the Andy Hill Care Fund to Advance...Aptevo Secures $1.5 Million Non-Dilutive Research Grant from the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Im... | 8-K7.01 | 2026-06-30 |
| The project period is expected to extend through June 2028, subject to earlier termination in a...On June 29, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into a Grant Award Agreement (the “Agreement”) with the Andy Hill Cancer... | 8-K1.01 | 2026-06-30 |
| Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Developme...Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by... | 8-K7.01 | 2026-05-27 |
| Sale of Shares to NiowaveThe description of the issuance and sale of the shares of Common Stock pursuant to the Stock Purchase Agreement set forth under Item 1.01 a... | 8-K3.02 | 2026-05-27 |
| Collaboration Agreement and Supply Agreement with NiowaveCollaboration Agreement and Supply Agreement with Niowave | 8-K1.01 | 2026-05-27 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.